PainTEQ's 'Deal of the Year' Win Signals a New Era for MedTech

TAMPA, FL – March 10, 2026 – Tampa-based medical device innovator PainTEQ has secured the prestigious "VC/PE Deal of the Year" award, a recognition that highlights the convergence of sophisticated investment, groundbreaking clinical technology, and the rise of Florida's business landscape. The honor, bestowed at the Annual Tampa Bay Dealmaker Summit on February 26th, celebrates the company's landmark majority growth recapitalization and cements its status as a leader in minimally invasive pain management.

The award acknowledges a pivotal transaction co-led by prominent healthcare investors Windham Capital Partners and Signet Healthcare Partners. This financial maneuver is set to accelerate the adoption of PainTEQ's flagship LinQ SI Joint Stabilization System, a therapy designed to alleviate a common and often debilitating form of lower back pain. The recognition is more than a local accolade; it's a national signal of investor confidence in a company aiming to set a new standard of care for patients suffering from sacroiliac (SI) joint dysfunction.

"PainTEQ's deal stood out for its strategic clarity and its real-world impact—this is exactly the kind of growth story the Tampa Bay Dealmaker Summit was created to celebrate," said Silvana Capaldi, President of DealMaker Forum, the organization behind the summit.

A Landmark Deal for a New Standard of Care

The financial transaction at the heart of the award is a majority growth recapitalization, a strategic move where investment firms acquire a majority stake to fuel aggressive expansion. This infusion of capital is earmarked for funding new clinical studies, developing next-generation products, and expanding PainTEQ's commercial footprint across the United States. For investors, the deal represents a bet not just on a product, but on a paradigm shift in treating chronic pain.

"This honor spotlights a partnership rooted in deep alignment," said David Kereiakes, Managing Partner at Windham Capital Partners, a firm known for investing at the intersection of medical technology and digital health. "It confirms we aren't just investing in a company; we are backing a new standard of care."

This sentiment was echoed by the co-leading investment firm. Ashley Friedman, Managing Director at Signet Healthcare Partners, added, "This recognition underscores the caliber of the platform we are building. Winning against a competitive field reinforces our conviction and the strength of the PainTEQ mission."

The deal also included a new equity investment from MVolution Partners, which had previously provided PainTEQ with $35 million in non-dilutive, intellectual property-backed growth capital in July 2023. This history demonstrates a sustained, strategic approach to financing that has allowed the company to build a robust foundation for its current growth phase. The complex and successful transaction was facilitated by financial advisor Raymond James.

Innovating Beyond Back Pain

While the financial deal captured headlines, the foundation of PainTEQ's success lies in its clinical innovation. The company's LinQ SI Joint Stabilization System targets sacroiliac joint dysfunction, a condition estimated to be the source of 15% to 30% of all chronic lower back pain cases. This common ailment, which can cause pain in the lower back, buttocks, and legs, is frequently underdiagnosed or mistaken for other spinal issues.

LinQ offers a minimally invasive, outpatient procedure that provides immediate stability to the SI joint. Using a posterior approach that avoids major nerves and blood vessels, a single, small allograft implant is placed to stabilize the joint and encourage long-term fusion. The procedure typically takes less than an hour, and patients often return home the same day, resuming most daily activities within weeks.

This approach stands in contrast to older, more invasive surgical methods and even some minimally invasive techniques that use a lateral approach, which carries a higher risk of complications. The company's claims are backed by a growing mountain of clinical evidence.

The landmark SECURE study, the largest clinical trial for a posterior SI joint fusion device, demonstrated significant positive outcomes. At 12 months, patients reported an average pain score reduction of 43.3 points on the Visual Analog Scale (VAS) and a 25.3-point improvement on the Oswestry Disability Index (ODI). The study also noted an exceptional safety profile, with no implant-related serious adverse events.

Further reinforcing these findings, the largest real-world analysis of the LinQ system, published in late 2025 and covering 258 patients, showed a remarkable 6-point average reduction in pain scores on the Numeric Rating Scale (NRS) at a mean follow-up of 1.75 years—well above the threshold for what is considered a clinically important difference. Critically, no serious adverse events were reported in this large patient cohort.

Another study highlighted LinQ as an effective "salvage" therapy, providing an average of 67.6% pain relief for patients who had failed to find relief from other advanced treatments like spinal cord stimulators and even previous lumbar fusion surgeries.

Fueling Tampa Bay's Economic Engine

PainTEQ's victory at the Palma Ceia Golf & Country Club is also a story of regional triumph. The Tampa Bay Dealmaker Summit, an initiative of the DealMaker Forum in partnership with the Lowth Entrepreneurship Center at The University of Tampa, is a cornerstone of the area's effort to build a vibrant ecosystem for entrepreneurs and investors.

The award validates this effort, showcasing how a local company can attract top-tier national investment and achieve a national profile. It positions Tampa Bay not just as a desirable place to live, but as a burgeoning hub for the high-growth healthcare and technology sectors.

PainTEQ's leadership has been an active participant in this local ecosystem, fostering the very connections celebrated by the summit. The company's success serves as a powerful beacon for other regional startups, demonstrating that world-class innovation and significant capital can converge far from traditional tech and finance hubs.

Shanth Thiyagalingam, Chief Executive Officer at PainTEQ, framed the award in the context of a collective mission. "This wasn't just a transaction; it represents a shared vision to build something enduring for patients suffering from SI joint dysfunction everywhere," he stated. "Our success is a direct result of our team's relentless execution through uncertainty, the bold belief of globally recognized medical device investors, and the trust of our physician partners in the LinQ therapy."

By uniting visionary investors with a clinically proven, patient-focused technology, PainTEQ's award-winning deal does more than just promise future growth; it delivers a compelling narrative about the modern path to success in the medical device industry.